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ORIGINAL ARTICLE
Minimal residual disease detection with tumor-speciﬁc CD160
correlates with event-free survival in chronic lymphocytic
leukemia
TW Farren1,2, J Giustiniani3, M Fanous2, F Liu2, MG Macey1, F Wright4, A Prentice4, A Nathwani5 and SG Agrawal1,2
In chronic lymphocytic leukemia (CLL), the detection of minimal residual disease (MRD) correlates with outcome in the trial setting.
However, MRD assessment does not guide routine clinical management and its assessment remains complex. We incorporated
detection of the B cell, tumor-speciﬁc antigen CD160 to develop a single-tube, ﬂow cytometry assay (CD160FCA) for CLL MRD to a
threshold of 10− 4 to 10− 5. One hundred and eighty-seven patients treated for CLL were enrolled. Utilizing the CD160FCA
methodology, there was a high level of comparison between blood and bone marrow (R= 0.87, Po0.001). In a validation cohort,
CD160FCA and the international standardised approach of the European Research Initiative on CLL group demonstrated high
concordance (R= 0.91, Po0.01). Patients in complete remission (CR) and CD160FCA negative had longer event-free survival (EFS)
(63 vs 16 months, Po0.01) and prolonged time to next treatment (60 vs 15 months, Po0.001) vs MRD positive patients; with a
median time to MRD positivity of 36 months. In multivariate analysis, CD160FCA MRD detection was independently predictive of
EFS in patients in CR and even predicted EFS in the good-risk cytogenetic subgroup. CD160FCA offers a simple assay for MRD
detection in CLL and gives prognostic information across different CLL risk groups.
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INTRODUCTION
The concept of minimal residual disease (MRD) assessment and
eradication in chronic lymphocytic leukemia (CLL) is still
considered a novel approach to patient care. Historically, the
investigation of MRD was not clinically relevant as treatment
protocols were designed with palliation in mind, and stabilising
symptoms with alkylating agents and complete remission (CR)
rates were low.1–3 However, newer chemo-immunotherapeutic
regimens have achieved CR rates of 60–70%, and have evaluated
MRD in this context.4,5 Nevertheless, relapse is inevitable after an
initial CR due to low-level residual cells. CR is currently deﬁned as
the absence of constitutional symptoms and organomegaly,
absolute neutrophil count ⩾ 1500 per microlitre, a platelet count
4100× 109/l and a hemoglobin level 411.0 g/dl; the bone
marrow (BM) must be normocellular with o30% lymphocytes.6
MRD assessment can stratify patients in CR into MRD-positive and
-negative groups, with MRD-negative patients having a survival
advantage.4,7–9
MRD assessment in CLL can be demonstrated using either
ﬂow cytometry or allele-speciﬁc polymerase chain reaction
(PCR).10− 12 Although allele-speciﬁc PCR has a high sensitivity
(1 in 106), it is complex, expensive and a pre-treatment sample is a
prerequisite. The European Research Initiative on CLL have
proposed an international standardised ﬂow cytometric approach
(ISA) and compared it against real-time quantitative allele-speciﬁc
oligonucleotide immunoglobulin heavy chain gene PCR.10
The authors demonstrated concordant results between ﬂow
cytometry and real-time quantitative allele-speciﬁc oligonucleotide
immunoglobulin heavy chain gene PCR in 94.7% of cases.10,11
Peripheral blood (PB) analysis was at least as sensitive as BM for
MRD assessment, with the exception of treatment with Alemtu-
zumab, where BM samples were necessary.
The recent description of the restricted expression in the B-cell
lineage of the cell surface marker CD160 to malignant, but not
normal B-cells, makes it an ideal candidate marker for MRD
detection.13 In normal lymphocytes, CD160 is expressed on the
majority of circulating NK cells, a subset of cytotoxic T cells, but
not B cells.14,15 In CLL, CD160 mediates PI3K-dependent cellular
activation: upregulation of Bcl-2, Bcl-XL, improved in vitro survival
and cytokine secretion.16
There is near-universal expression of CD160 in CLL, monoclonal
B-cell lymphocytosis and hairy cell leukemia, which was estab-
lished using the CD160 ﬂow cytometric assay (CD160FCA).13 In this
report, we have investigated the utility of CD160FCA for MRD
detection in CLL and compared it with the current recommended
standard.10
PATIENTS AND METHODS
CD160 ﬂow cytometric assay for MRD detection
CD160FCA is a six-color assay, which has been slightly modiﬁed since
previously reported, but still uses the same whole-blood analysis protocol
and simple gating strategy that has been modiﬁed by one additional CD45
vs Side Scatter gate since previously reported.13 The CD160FCA
incorporates CD2-FITC (Clone S5.2), CD5-APC (Clone L17F12), CD19-
PerCPcy5.5 (Clone SJ25C1), CD23-APC (Clone EBVCS-5) and CD45 V500
(Clone Hi30) (BD Biosciences, Oxford, UK); CD160-PE (Clone BY55; IgM
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isotype; Immunotech, Beckman Coulter, Marseilles, France). All monoclonal
antibodies used in the study underwent titration to determine the
optimum concentration of monoclonal antibody for a given number of
cells. To determine the optimal saturating concentration, a serial doubling
dilution of the ﬂuorochrome-labeled antibody was tested over a range
above and below that of the manufacturer's recommendations. The
intrinsic spectral overlap of the different ﬂuorochromes in the CD160FCA
was corrected using compensation matrices and automatic compensation
beads (BD Biosciences). The CD160FCA underwent steric hindrance
analysis to assess if antigen expression was reduced or absent if the
antibodies were binding the same macromolecular complex. Further
evaluation for reagent interaction altering assay performance was
efﬁciently assessed by comparing the median ﬂuorescence intensity of a
sample prepared with all antibodies of interest with a series of
preparations in which each lacks one of the component ﬂuorochrome-
conjugated monoclonal antibodies.
Where possible 500 000 events were acquired for each MRD patient on a
FACS Canto II with standard laser and ﬁlter conﬁguration (BD Biosciences).
Daily calibration of the instrument was performed using CS&T beads (BD
Biosciences). Data were acquired and analyzed by means of BD FACS Diva
clinical software (version 6.1.3) for enhanced acquisition analysis, which
determined the median ﬂuorescence intensity of CD160 on the CD2neg
CD5+CD19+CD23+ population. Residual disease was based on the number
of events co-expressing CD2negCD5+CD19+CD23+CD160+ out of the total
number of events collected.
Simulation of MRD
To assess the utility of CD160 in the monitoring of MRD and the possible
limit of detection, samples simulating MRD specimens were prepared by
mixing separated untreated CLL cells (n=5) with normal leukocytes (whole
blood) from donors. Serial dilutions were performed from 1:1–1:100 000 to
determine the sensitivity and speciﬁcity of the assay.
CD160 PCR analysis
Qualitative MRD assessment was performed on total RNA extracted from
freshly isolated CD19+ B-cells as previously described.13 The speciﬁc
primers for complementary DNA synthesis were designed on published
sequences from human CD160 (NM_007053): BY-TM (5′-GCCAG
AAGCCAGAAGTCAGGTATCCG-3′) (forward) and BY3UN (5′-CCTGTGCCC
TGTTGCATTCTTC-3′) (reverse). In brief, all samples were subjected to
denaturation (94 °C for 30 s), annealing (60 °C for 30 s) and extension (72 °C
for 90 s) steps for 35 cycles. For the CD160 complementary DNA
sequencing, the open-reading frame was ampliﬁed by PCR with BY01
and BY3UN primers and Taq High Fidelity (Life Technologies, Paisley, UK).
PCR product was puriﬁed (qiaex II, Qiagen) and analyzed with the following
primer sequences: forward primers BY01 (5'-TGCAGGATGCTGTTGGAACCC-3')
and BY03 (3′-TCAGCCTGAACTGAACTGAGAGTGCCTTC-5′). reverse primers
BY02 (5'-CAGCTGAGACTTAAAAGGGATC-3'), BY04 (3'-CACCAACACCATCTATC
CCAG-5') and BY3UN (5′-CCTGTGCCCTGTTGCATTCTTC-3′).
Patients
CLL was diagnosed in 187 patients including correlation with BM aspirate,
trephine, lymph node and spleen histology, ﬂow cytometry and
karyotyping when required.6,17,18 Patients provided informed consent.
The National Research Ethics Service, East London and the City HA Local
Research Ethics Committee approved non-diagnostic analyses, and written
informed consent was obtained (REC reference 07/Q0604/34).
Pilot study recruitment
A pilot cohort consisted of 52 patients diagnosed with CLL. Samples were
taken for routine diagnosis, then where possible at 3, 6, 9 and 12 months
following treatment for the assessment of MRD. This consecutive set of
patients received a variety of therapies: chlorambucil-based therapy (n= 7),
ﬂudarabine (n= 6), ﬂudarabine+cyclophosphamide (n= 22), ﬂudarabine
+cyclophosphamide+rituximab (n= 11), alemtuzumab (n=6). Following
completion of therapy, response assessment using the MRD ﬂow assay was
compared against qualitative RT-PCR.
MRD assessment by CD160FCA in paired BM and PB (Pilot Cohort)
In a subset of 35 patients from the pilot cohort, assessments of MRD using
CD160FCA were performed in paired blood and BM samples prior, during
or within 3 months after treatment. Sample preparation was identical for
both PB and BM samples and run using the described sequential gating
strategy.
Prospective validation cohort
One hundred and thirty-ﬁve patients were followed prospectively to
validate the pilot data: a subset (n= 38) underwent direct comparison
against the current gold standard ISA approach; and a separate group of
patients were assessed for outcomes (n=97). In the CD160FCA comparison
with the European Research Initiative on CLL ISA methodology, a total of
48 specimens (from 38 patients), were simultaneously analyzed in four
different centers. Two centers (center 1 (C1) and C2) used the ISA
described by Rawstron et al,10 according to their standard operating
procedures, whereas two other centers (C3 and C4) used the CD160FCA.13
Patients were recruited irrespective of their treatment regimen: ﬂudarabine+
cyclophosphamide (n = 11), ﬂudarabine+cyclophosphamide+rituximab
(n = 9), ﬂudarabine+cyclophosphamide+rituximab-Lumiliximab (n = 3),
Chlorambucil-R (n=6), Chlorambucil-Ofatumuab (n= 2), Alemtuzumab
(n=3), allogeneic hemopoietic stem cell transplant (HSCT)(n= 4).
Complete outcome data were available on 97/135 patients, who were
repeatedly assessed as part of their ongoing monitoring for MRD by
CD160FCA. Patients were assessed for time to disease detection (TTD) by
CD160FCA, and correlated with known prognostic indicators (ZAP-70,
CD38, cytogenetics and serum beta-2-microglobulin, β2M), as well as
event-free survival (EFS, deﬁned as time to next treatment, asymptomatic
relapse or death). EFS and MRD kinetics for this cohort of patients were
evaluated by Kaplan–Meier estimates and log-rank tests for trend based on
ﬁrst-line treatment (patient characteristics in Table 1).
Statistical analysis
Standard epidemiological approaches were used to calculate diagnostic
indices of sensitivity and speciﬁcity. To determine non-random associa-
tions, the two-tailed nonparametric Fisher’s exact test was used. Non-
parametric correlation coefﬁcient r (Spearman Rank) was calculated to
compare the MRD results obtained from the different centers. To
determine differences in MFI of MRD populations, the two-tailed t-test
based on the mean± s.e.m. was used. Comparison of Kaplan–Meier survival
Table 1. Patient characteristics for patients in the validation cohort
with response data
Characteristic No. %
No. of patients 97 100
Age, years
Median 58
Range 31–77
Sex
Male 67 69
Female 30 31
Stage at diagnosisa
A 62 64
B 18 18
C 17 18
First -ine therapy
Chemotherapyb 58 60
Immunotherapy (± chemotherapy)c 39 40
Response to ﬁrst-line therapy
Complete 42 43
Partial 49 51
No response 6 6
aStage of patients at diagnosis, not at time of therapy. bChlorambucil
monotherapy (CBL), ﬂudarabine monotherapy (FDR), ﬂudarabine and
cyclophosphamide (FC). cCampath, CBL+rituximab, FDR+rituximab,
FC+rituximab.
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curves determining EFS and TTD was obtained by the nonparametric
Mantel-Cox log-rank test. Levels of signiﬁcance were determined as
o0.05. The hazard ratio (HR) was derived from the Cox regression model
indicating any hazard or chance of adverse or beneﬁcial events.19
Statistical analysis was performed using GraphPad PRISM 5.0d for
Macintosh (GraphPad software, CA, USA) and SPSS Statistics for Macintosh,
Version 22.0 (Armonk, NY: IBM Corp).
RESULTS
Simulation of MRD
The feasibility of using CD160FCA to detect MRD for CLL was
assessed with a simulation assay. Samples from ﬁve patients with
CLL were serially diluted in normal leukocytes, such that the CLL
cells represented an actual tumor burden as low as 0.01% of the
total lymphocyte population. A lower threshold of 10− 4 represents
the cutoff below which patients are known to have a superior
outcome,20 therefore the detection of MRD to levels o0.01%
were recorded as o10− 4. Qualitative PCR for CD160 transcripts
was also performed on puriﬁed B-cells (Supplementary Figure 1).
Normalizing the data to the true malignant expression being
100%, results demonstrated a good correlation between theore-
tical (calculated from 100%) and observed MRD (actual analyzed
MRD) (Figure 1a; R2 = 0.98). Light-chain (LC) restriction was
detectable by conventional methodologies within the CD5+
CD19+ B-cell population, but only when the CLL tumor burden
represented ~ 40% of B-cells (data not shown). This demonstrates
the limited utility of LC-restriction when dealing with low B-cell
numbers. CLL cells could be reliably identiﬁed using CD160FCA to
a level of 10− 4 (Figure 1a). However, the CD160FCA was able to
detect MRD to a level of 10− 5 (Supplementary Figure 2).
Pilot cohort—MRD assessment by CD160FCA and RT-PCR
for CD160
A pilot cohort was recruited consisting of 52 cases with MRD
analysis performed after a minimum of 3 months following
cessation of therapy. Using 10− 4 as the cutoff, CD160FCA
identiﬁed two groups of MRD-positive or -negative patients
(P= 0.01, Figure 1b). RT-PCR for CD160 was performed on puriﬁed
CD19+ B-cells (Supplementary Figure 1), which demonstrated
concordant results with CD160FCA in 94% of patients. There was a
strong statistical correlation between the CD160FCA and PCR
results (Fisher's exact test Po0.0001, odds ratio 282).
BM or PB for MRD detection
Within a subset of the pilot cohort, MRD levels were assessed in
paired PB and BM samples from 35 patients utilizing CD160FCA
where results were within the quantitative range. Concordant PB
and BM results were demonstrated in 30/35 cases, irrespective of
the treatment regimen (Po0.001). A signiﬁcant correlation was
observed between PB and BM CD160FCA results (Spearman rank
correlation R= 0.87, Po0.001) (Figure 1c).
Prospective validation of CD160FCA
A total of 135 patients were prospectively evaluated for MRD by
the CD160FCA. The separation of MRD-negative and -positive
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Figure 1. MRD detection by CD160FCA and correlation with PCR in
the pilot cohort. (a) The theoretical MRD expression (calculated,
x axis) is plotted against the observed MRD expression (actual
analyzed MRD analysis, y axis) by CD160FCA. The results are the
percentage expression of CD160 of the total leukocyte population.
The comparative RT-PCR results are demonstrated at the top of the
graph above the corresponding dilution. The R2 linear regression
value for observed expression vs theoretical expression was
R2= 0.98. (b) Separation of MRD-positive and MRD-negative
populations based on CD160FCA assessment (P= 0.01). (c) MRD
assessment in paired peripheral blood and bone marrow CLL cells as
determined by the CD160FCA (n= 47), irrespective of the treatment
regimen (Spearman Rank R= 0.87, Po0.0001).
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cases by CD160FCA is shown in Figure 1b, which validates the
results observed in the pilot cohort.
CD160FCA vs ISA methodology in the validation cohort
A direct comparison between CD160FCA and ISA was performed
involving four centers, using 49 samples from 38 patients. Results
were calculated locally and then reported centrally. Operators
produced concordant results in 44/49 samples (89.7%), with 3/49
cases being CD160FCApos but ISAneg, and 2/49 cases being
CD160FCAneg but ISApos. MRD results were reported either as a
percentage or the absolute number of cells. Regardless of the
reporting method, there was a strong correlation between the two
methodologies (Spearman r= 0.91, Po0.001, Figure 2a). Assessing
assay variability between centers performing the same methodol-
ogy, the CD160FCA centers had a higher level of concordance vs
the ISA methodology (Spearman r= 0.94 and 0.90, respectively,
Po0.01).
A potential advance in the analysis and reporting of MRD data
would be the use of MFI expression instead of percentage
positivity. The intensity of CD160 expression was assessed for both
centers performing the CD160FCA and each had signiﬁcantly
different MFIs between their MRD-positive and -negative patients
(P= 0.0002 and P= 0.0005, Figure 2b). When combining the results
from both centers, the mean (± s.e.m.) for MRD-positive patients
was 341.3 ( ±52.61) and 76.38 (±12.14) if MRD was negative.
Despite the differences in MFI between both centers, attributable
to the use of different analysers and voltage setup, the MFI
between MRD-negative and -positive populations was still
signiﬁcantly different.
MRD detection by CD160FCA correlates with known prognostic
markers in CLL
TTD following therapy, as detected by the CD160FCA in patients in
CR or PR, was evaluated by univariate analysis for known
prognostic markers in 97 patients, namely, cytogenetics, CD38
expression, ZAP-70 expression and serum β2M levels.
21,22
Univariate analysis demonstrated that poor risk cytogenetic status:
17p deletion (n= 23) or 11q deletion (n= 11) had a signiﬁcantly
shorter TTD (2.95 and 4.01 months, respectively) when compared
with trisomy 12 (8.02 months; n= 6), normal karyotype
(20.97 months n= 17) and 13q deletion (25.02 months, log-rank
Po0.01, Figure 3a, n= 40).
CD38 status and elevated β2M prior to treatment were
predictors of TTD based on residual disease assessment by the
CD160FCA: CD38+ (n= 44) vs CD38- (n= 53): 6.05 vs 21.99 months;
P= 0.04, HR: 1.38 (Figure 3b); β2M elevated (n= 68) vs β2M normal
(n= 21): 6.03 vs 28.01 months; Po0.01, HR: 2.32 (Figure 3c). Those
patients who were ZAP-70 positive had shorter TTD compared
with those who were negative: ZAP-70+ (n= 26) vs ZAP-70-
(n= 42: 9.07 vs 24.98 months; P= 0.04, HR: 1.65 (Figure 3d).
CD160FCA MRD positivity correlates with shorter EFS following
ﬁrst-line treatment
Within the validation cohort, complete outcome data were
available on 97 patients, who were followed up with MRD
assessment using CD160FCA (Table 1). Responses were classiﬁed
using the current National Cancer Institute guidelines and
CD160FCA MRD assessment performed at regular intervals (range
1 to 81 months). Of 43 patients in CR, those who were CD160FCA
MRD+ (n= 11), had a signiﬁcantly shorter EFS than patients in CR
and MRD negative (n= 32) (16 vs 63 months, respectively,
Po0.001, HR 6.17, Figure 4a). Patients who achieved a CR but
were MRD positive by CD160FCA had a median EFS similar to
those patients achieving a partial remission based on iwCLL
response (n= 48) (12 months, Figure 4a). A trend was observed in
median EFS for patients in PR and MRD positive (n= 38) vs MRD
negative (with PR primarily due to residual lymphadenopathy ±
residual cytopenias) (n= 10) (12.5 months vs 25.5 months,
respectively, P= 0.12, HR 1.78 Supplementary Figure 3). There
were six patients who did not respond to therapy. Patients who
were in CR and MRD negative by the CD160FCA had a median
time of 36 months to conversion to MRD positivity (Figure 4b) and
a median time to next therapy of 60 months. Those patients in CR
and MRD positive by CD160FCA analysis had a median time to
next therapy of 15 months (Po0.001).
CD160FCA MRD status is an independent prognostic marker of
EFS following ﬁrst-line treatment
In univariate analysis (n= 97, except ZAP-70 where n= 69), all the
parameters assessed—MRD assessment by CD160FCA, cytoge-
netic status, Zap-70, CD38, elevated β2M and clinical response—
were predictive of EFS. However, in multivariate analysis, only
MRD assessment by CD160FCA (Po0.01, HR 5.0, Table 2) and Zap-
70, status remained independent predictors of EFS (P= 0.04, HR
1.90, Table 2). As ZAP-70 data were not available in 28 cases, Cox
regression mutivariate analysis (n= 97) was performed omitting
ZAP-70, which demonstrated that not only MRD positivity by
CD160FCA remained signiﬁcant (P= 0.03, HR 2.41), but also
cytogenetic status (P= 0.01, HR 2.04) was signiﬁcant.
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Figure 2. MRD detection by CD160FCA vs International Standar-
dized Protocols in the validation cohort. (a) Comparative assessment
of CD160FCA MRD positivity as a percentage of total leucocytes
against the ISA methodology (n= 48 samples, Po0.001, R= 0.91).
(b) MRD-positive and -negative cohorts based on the median
ﬂuorescence intensity (MFI) of the CD2neg/CD5+/CD19+/CD23+/
CD160+ population.
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In terms of cytogenetic prognostication, patients with good-
risk/intermediate cytogenetics (13q-, +12, normal karyotype) had a
longer EFS following ﬁrst-line therapy compared with poor-risk
patients (17p- and 11q-; 38.5 vs 9.99 months, respectively,
Po0.01). Interestingly, patients with good-risk cytogenetics could
be further stratiﬁed based on their CD160FCA MRD status:
MRD-positive patients (n= 25) had signiﬁcantly worse EFS vs
MRD-negative patients (n= 32) (18 vs 61 months, Po0.01,
Supplementary Figure 4).
DISCUSSION
Current chemo-immunotherapy regimens have led to a paradigm
shift in CLL management with successful eradication of the
disease burden, achievement of CR and prolongation of survival.
However, conventional CR can be associated with a signiﬁcant
residual disease burden and MRD assessment—as evaluated by
sensitive ﬂow cytometric and molecular techniques—can further
deﬁne responses in patients in CR to those as MRD-negative CR
with signiﬁcantly improved PFS and OS compared with those who
achieve CR but are MRD positive.8,20 This study assesses the
impact and prognostic signiﬁcance of MRD in CLL utilizing a
simpliﬁed assay, in terms of both the number of surface proteins
targeted—thereby reducing the number of monoclonal antibo-
dies—and a simpler gating strategy. This was achieved by
incorporating the B-lineage tumor-speciﬁc biomarker, CD160,13,16
for MRD detection using a new immunophenotypic assay
(CD160FCA).
The real-world data reported in this study derive from patients
with CLL, treated and followed up at our institution, regardless of
the treatment regimen. MRD testing was performed in routine
diagnostic laboratories, with MRD positivity deﬁned as a level of
MRD40.01% (10− 4; that is,41 in 10 000 cells). The use of CD160
has simpliﬁed the quantiﬁcation of MRD to a level of at least 10− 4
in both PB and BM (Figure 1b), with the potential to detect to a
level of o0.001% (Supplementary Figure 2). Furthermore, it
remains informative even following treatment regimens using
Rituximab and Alemtuzumab. Evaluation of CD160FCA against the
current gold standard (ISA) showed there was a high concordance
between the two assays (Po0.01). The clinical signiﬁcance of
CD160FCA MRD monitoring was shown in patients following ﬁrst-
line treatment: those patients in CR and MRD-negative by
CD160FCA had a prolonged EFS (63 months n= 32) compared
with patients in CR but CD160FCA MRD+ (16 months, n= 11,
Po0.01, Figure 4a). For those patients in PR according to the
National Cancer Institute guidelines,6 outcome was similar to
those patients in CR but MRD positive by CD160FCA (Figure 4a).
Extending the analysis to include patients having second-line
therapy or greater, MRD negativity was still associated with a
prolonged EFS (CR-MRD negative 48 months vs CR-MRD positive
24 months, Po0.01, data not shown).
Achieving MRD negativity is associated with better clinical
outcomes irrespective of treatment regimen and can be
considered a valid clinical end point.20 In terms of EFS, biological
and clinical prognostic indicators were added into a multivariate
analysis model in order to observe the prognostic impact of MRD
on survival. Detection of residual disease by CD160FCA and
ZAP-70 status remained independent prognostic indicators of EFS
when used in a multivariate analysis model (Table 2). These
observations show that MRD-negative remissions, based on
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Figure 3. Correlation of time to detection of CLL by CD160FCA with known indicators of prognostication. (a) Time to detection (TTD) based on
cytogenetic abnormality at diagnosis (n= 142). Median TTD: 13qdel was 25 months (n= 40); normal karyotype was 21 months (n= 17);
Trisomy 12 was 8 months (n= 6); 11qdel was 4 months (n= 11); and p53 mutation/17pdel was 3 months (n= 23). (b) TTD based on CD38
expression at diagnosis was shorter for CD38-positive patients (n= 44) than those CD38-negative (n= 53) (6 months vs 22 months,
respectively, HR: 1.38, P= 0.04). (c) TTD based on beta-2-microglobulin (β2M, n= 89). Median TTD for elevated β2M: 6 months (n= 68) vs normal
β2M: 28 months (n= 21, HR 2.32, Po0.01). (d) TTD based on ZAP-70 expression. Median TTD for high expression: 9 months (n= 26) vs low/
absent protein expression 25 months (n= 42, HR: 1.65, P= 0.04).
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CD160FCA analysis, translate into improved response duration
and that response duration was concordant with known pre-
treatment indicators of prognostication.
In conclusion, targeting CD160, a B-lineage, tumor-speciﬁc
marker, has led to the successful development of a simple single-
tube, ﬂow cytometric MRD assay, which differs from other
approaches that do not contain tumor-speciﬁc targets and require
more than a single tube. This approach avoids the need for a large
number of monoclonal antibodies incorporated into multi-tube
panels, with complex gating. We have used CD160FCA for both
the diagnostic13 and MRD settings, which is of practical
importance in an area where complexity and cost are continually
growing. Automation of CD160FCA MRD analysis (using MFI) may
allow a standardized assay to be developed, which would meet
the requirements of regulatory authorities for MRD as a surrogate
end point for clinical trials. The role of CD160 in MRD analysis has
emerged as an independent prognostic marker, which needs to
be repeated, in a larger multi-center trial.
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